Of note, hyperactivation of mTORC1 signaling is associated with several neurological disorders, such as autism, AD, and tuberous sclerosis, and suppression of mTORC1 using compounds that inhibit mTOR signaling has been shown to be an effective treatment in several clinical trials (Caccamo et al., 2014; Crino, 2016; Kaur & Sharma, 2017). The gene discussed is MTOR; the disease is tuberous sclerosis.